31/100Is VERA-Vera Therapeutics, a buy?
Tuesday 15 September 2026
Why now: TRUTAKNA received accelerated approval and has begun its United States launch, moving VERA from a development story to an early commercial-execution story. The next decisive catalyst is the ORIGIN 3 final efficacy analysis expected during the third quarter of 2026, but the share price is still technically weak.
Upside: The supplied 14-analyst consensus target is $86.75, implying 154.8% upside from the $34.05 premarket print. That gap reflects expectations for successful launch uptake and a favorable confirmatory clinical outcome, not established earnings power.
Risks: The company has not yet demonstrated recurring product revenue in the supplied annual data and its financial profile shows large losses, negative free cash flow, and dilution. A disappointing ORIGIN 3 result or weak insurer and prescriber uptake could sharply reduce the commercial case.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free — no credit card needed.
Scorecard
| Scorecard | 31/100 | |
|---|---|---|
| Company Detail | VERA - Vera Therapeutics, Inc. | |
| Price as at 14 September 2026 | $34.05 | |
| Market cap | $2.4B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 4/20 | |
| Rev/EPS Momentum /20 | 0/20 | |
| Business Quality /15 | 10/15 | |
| Balance Sheet /15 | 3/15 | |
| Valuation /10 | 2/10 | |
| Industry Relative Strength /10 | 4/10 | |
| Macro / Sector Tailwind /10 | 8/10 | |
| Growth | ||
| Cash runway | 0.20 yr | |
| Revenue YoY | — | |
| EPS YoY | -69.5% | |
| FCF YoY | -78.2% | |
| Gross margin | — | |
| Valuation & Trend | ||
| Trailing P/E | neg | |
| Forward P/E | — | |
| RSI (14d) | 49 | |
| vs 50d SMA | -2.9% | |
| Support cushion | −3.6% | |
| Sentiment | ||
| Wall Street verdict | Aligned | |
| News tone | Positive | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3--2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis — Tuesday 15 September 2026
Marshall Fordyce has been Founder and Chief Executive Officer of Vera Therapeutics since founding the company in 2016.
Sean Grant has been Chief Financial Officer of Vera Therapeutics since July 2021.
David Johnson has been Chief Operating Officer of Vera Therapeutics since July 2024.
Receiver of capital expenditure: No: Vera is a drug developer and commercial-stage biotechnology company, so its sales depend on prescriptions, insurer coverage, and patient access rather than on customer capital-spending budgets.
Main customers
- Adults with primary immunoglobulin A nephropathy (TRUTAKNA is approved for adult patients at risk for disease progression.)
- Nephrologists and kidney-care practices (These prescribers identify eligible patients and drive early adoption of the medicine.)
- VERA has an approved first-in-class medicine that addresses two immune pathways involved in primary immunoglobulin A nephropathy, giving it a more tangible business than a typical pre-approval biotechnology company.
- The company also has an experienced commercial operator in the chief operating role at the point of launch.
- The long-term opportunity depends on proving that early patient access and nephrologist adoption can become a durable sales franchise, while confirmatory data supports a path from accelerated to full approval.
Show 1 headline from the last 7d
Scores 31 out of 100. a mixed overall grade. Sector fit scored highest. Business quality was fair but not a standout driver. Relative strength versus its industry and chart setup weighed on the total. The score is capped because VERA has no completed revenue base in the supplied annual figures, remains deeply loss-making and cash-burning, and has had severe five-year share dilution. The chart is also below both its 50-day and 200-day moving averages, with no confirmed breakout and below-normal volume. Mechanical cap: latest annual net income ≤ 0. Balance Sheet ≤ 3/15, Rev/EPS ≤ 0/20, overall ≤ 50/100.
Component scores are on the scorecard above.
- The current premarket print is $34.05, down 2.85% from the prior close.
- The last completed daily bar had recovered the 50-day average six sessions earlier but was again 2.9% below it, while sitting 14.0% below the 200-day average and 38.8% below the 52-week high.
- A 7.7% 20-day gain shows a rebound attempt, but volume remains below its longer baseline, relative industry strength is only 45.5, and price remains well below the $40.13 resistance level.
- The supplied annual figures show no revenue, a $299.62 million net loss, and $241.73 million of negative free cash flow.
- Latest figures show $48.88 million of cash and an estimated 0.2 years of runway, alongside a current ratio of 10.9 and negative net debt to earnings before interest, taxes, depreciation, and amortization; it also reports that share count rose 1,632.23% over five years.
- These are major red flags, even though the business has since reached commercial launch and the company reported a stronger liquidity position in its most recent quarterly release.
Cash runway: 0.20 yr ($49M cash ÷ $242M/yr burn, latest fiscal year).
Upcoming (1–6 months)
- ORIGIN 3 final efficacy analysis expected in the third quarter of 2026 and the planned supplemental approval filing expected in the fourth quarter of 2026.
Ongoing
- Early TRUTAKNA prescription demand, insurer coverage, patient starts, cash use, and whether price can reclaim the 50-day average before challenging $40.13.
Risks
- Accelerated approval requires confirmatory support, and the commercial launch may be slower than expected if coverage decisions, physician behavior, or patient access prove difficult.
- The supplied financial data shows a short cash runway, persistent losses, negative free cash flow, and a history of heavy dilution, all of which could require further financing.
Breaks the thesis
- A materially unfavorable ORIGIN 3 efficacy result, a delay to the planned supplemental filing, or launch evidence that fails to establish meaningful demand would break the long-term commercial thesis.
- Technically, a sustained daily close below $30.00 would signal that the current recovery attempt has failed.